Related Experiment Videos
Gemcitabine and cisplatin in refractory malignant lymphoma
Agustín Avilés1, Natividad Neri, Judith Huerta-Guzmán
1Oncology Research Unit, Mexican Social Security Institute, Mexico City, Mexico. agaviles@avantel.net
Oncology
|June 26, 2004
Summary
High-dose gemcitabine and cisplatin combination therapy shows promise for refractory diffuse large cell lymphoma patients, demonstrating a 53% complete response rate with mild toxicity. Further follow-up is needed to confirm long-term efficacy in lymphoma treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Diffuse large cell lymphoma (DLCL) is an aggressive non-Hodgkin lymphoma.
- Primary refractory DLCL poses a significant treatment challenge.
- Limited effective salvage chemotherapy options exist for refractory DLCL.
Purpose of the Study:
- To evaluate the efficacy and safety of a high-dose gemcitabine-cisplatin combination regimen.
- To assess the treatment of primary refractory DLCL with high or high-intermediate clinical risk.
- To determine response rates, disease-free survival, and overall survival in this patient population.
Main Methods:
- A pilot study involving 30 patients with refractory DLCL.
- Treatment administered: gemcitabine (1.5 g/m2 IV) and cisplatin (50 mg/m2 IV) on a brief weekly schedule.
- No additional therapies were given post-chemotherapy.
Main Results:
- Achieved a 53% complete response rate.
- Observed only two relapses at the last follow-up.
- Reported 3-year actuarial disease-free survival of 87% and overall survival of 53%.
- Toxicity was mild and treatment was well tolerated, with no treatment-related deaths.
Conclusions:
- The gemcitabine-cisplatin combination is a promising treatment for refractory lymphoma patients.
- Low toxicity profile observed, suggesting good tolerability.
- Longer follow-up is required to validate these encouraging findings.
- Current research explores maintenance therapy with monoclonal antibodies (anti-CD20) to improve survival outcomes.